Advances in Treatment of Progressive Multifocal Leukoencephalopathy

Raphaël Bernard-Valnet*, Igor J. Koralnik, Renaud Du Pasquier

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

Progressive multifocal encephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by JC virus (JCV), which occurs in immunocompromised individuals. Management of PML relies on restoration of immunity within the CNS. However, when this restoration cannot be readily achieved, PML has a grim prognosis. Innovative strategies have shown promise in promoting anti-JCV immune responses, and include T-cell adoptive transfer or immune checkpoint inhibitor therapies. Conversely, management of immune reconstitution inflammatory syndrome, particularly in iatrogenic PML, remains a major challenge. In this paper, we review recent development in the treatment of PML. ANN NEUROL 2021;90:865–873.

Original languageEnglish (US)
Pages (from-to)865-873
Number of pages9
JournalAnnals of neurology
Volume90
Issue number6
DOIs
StatePublished - Dec 2021

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Advances in Treatment of Progressive Multifocal Leukoencephalopathy'. Together they form a unique fingerprint.

Cite this